Skip to main content
CAMBIUM BIO LIMITED logo

CAMBIUM BIO LIMITED — Investor Relations & Filings

Ticker · CMB ISIN · AU0000327769 ASX Professional, scientific and technical activities
Open in API
Filings indexed 504 across all filing types
Latest filing 2019-08-29 Capital/Financing Update
Country AU Australia
Listing ASX CMB

About CAMBIUM BIO LIMITED

https://www.cambium.bio

Cambium Bio Limited is a clinical-stage regenerative medicine company focused on developing innovative cellular therapies to treat unmet medical needs in ophthalmology and inflammatory diseases. The company's primary focus is on its lead candidate, EluRegen, a first-in-class topical biologic designed for the treatment of corneal epithelial defects and dry eye disease. Utilizing its proprietary technology platforms, the company aims to harness the regenerative potential of biologics to provide effective treatments for chronic conditions. In addition to its ophthalmic pipeline, the company maintains assets in the field of mesenchymal stem cell therapies, including Progenza, which targets osteoarthritis and neuropathic pain. The company emphasizes a data-driven approach to clinical development, seeking to improve patient outcomes through advanced tissue engineering and cell-based solutions.

Recent filings

Filing Released Lang Actions
Clarification to Announcement 2 pages 107.7KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 30 August 2019, clarifying the results of a non-renounceable rights issue and shortfall notification. It details the amount raised, share issuance, underwriting arrangements involving directors, and references a recent private placement. The content focuses on fundraising activities and capital structure changes. The document length is 3019 characters, which is relatively short and typical for an announcement rather than a full report. There is no detailed financial statement or comprehensive report content. Therefore, this document is best classified as a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes.
2019-08-29 English
Restructuring results in 50% reduction in operating costs 3 pages 127.3KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 13 August 2019 from Regeneus Ltd. It discusses the company's strategic restructuring, cost reductions, executive remuneration changes, and progress towards commercializing a product (Progenza) in Japan. The content focuses on operational updates, cost-saving initiatives, and management alignment with strategy rather than presenting financial statements or detailed financial results. There is no indication of quarterly or annual financial data, audit information, or earnings results. The document is a corporate update on restructuring and strategic focus, which fits best under Capital/Financing Update (CAP) as it relates to cost structure and funding strategy. It is not a report publication announcement or regulatory filing as it contains substantive operational information. Therefore, the classification is CAP with high confidence.
2019-08-12 English
Confirmation of Despatch of Offer Booklet 35 pages 1.5MB
Capital/Financing Update Classification · 100% confidence The document is an ASX announcement dated 13 August 2019 regarding an Entitlement Offer by Regeneus Ltd. It details the dispatch of the Offer Booklet and personalised Entitlement and Acceptance Form for a pro rata non-renounceable entitlement offer of new shares. The document includes detailed information about the offer, key dates, terms, and instructions for shareholders. It is not a financial report, earnings release, or management discussion but rather an update on a capital raising activity. The presence of terms like 'Entitlement Offer', 'Offer Booklet', 'new shares', 'issue price', and 'raising approximately AUD$3.2 million' clearly indicate this is a capital/financing update. The document is lengthy and substantive, not merely an announcement of a report publication or a brief notice. Therefore, the correct classification is Capital/Financing Update (CAP).
2019-08-12 English
Updated Investor Presentation 13 pages 598.4KB
Capital/Financing Update Classification · 95% confidence The document is titled 'Rights Issue Investor Presentation' and dated August 2019. It contains detailed information about a placement and entitlement offer of new shares, including terms of the offer, use of funds, value creation plans, portfolio of therapeutic candidates, patent portfolio updates, market data, investment risks, and a proforma consolidated statement of financial position. The content is clearly aimed at investors to inform them about the capital raising and strategic plans. There is no indication that this is a full financial report like an annual or interim report, nor is it a regulatory filing or announcement of voting results. The document is a detailed presentation focused on financing and investor information related to a rights issue. Therefore, the most appropriate classification is 'Capital/Financing Update' (CAP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2019-08-06 English
Placement Appendix 3B and Cleansing Statement 13 pages 511.6KB
Capital/Financing Update Classification · 95% confidence The document is titled 'Appendix 3B' and is an announcement related to a new issue of securities, specifically a placement of 29,250,000 fully paid ordinary shares by Regeneus Ltd. It includes detailed information about the class of securities, number issued, issue price, purpose of the issue, shareholder approvals, and calculation of placement capacity under ASX rules 7.1 and 7.1A. The document is a formal notification to the ASX (Australian Securities Exchange) about the issuance and quotation of additional securities. It does not contain financial statements, earnings data, management discussion, or audit information. Instead, it is a regulatory announcement about capital raising and share issuance. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2019-08-06 English
Letter to Shareholders - Non Renounceable Rights Issue 5 pages 1.3MB
Capital/Financing Update Classification · 100% confidence The document is a detailed notice to shareholders regarding a pro rata non-renounceable entitlement offer by Regeneus Ltd to raise capital. It includes terms of the offer, eligibility criteria, timetable, capital structure before and after the offer, and instructions for shareholders. The document is focused on informing shareholders about the capital raising event and the mechanics of the entitlement offer, including underwriting details and share allotment. There is no financial statement or comprehensive financial analysis present, nor is it a brief announcement or a transcript. The content aligns with a Capital/Financing Update, as it provides detailed information about a fundraising activity and changes to the capital structure. The document length (over 10,000 characters) and detailed content confirm it is not a mere announcement or regulatory filing. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2019-08-01 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.